Peter Lynch · Growth at a reasonable price (GARP)
Is Corcept Therapeutics Incorporated (CORT) a Peter Lynch Stock?
Does not fit Lynch's GARP criteria, growth too low or price too high.
30/100
Ne correspond pas
4/6 critères validés
Les critères de Peter Lynch, appliqués à CORT
PEG ≤ 1.0
clé-
EPS CAGR ≥ 15%
clé-0.5%
Revenue CAGR ≥ 10%
20.1%
Net margin > 0
6.2%
Comment CORT se classe selon d'autres stratégies
Données financières en direct
Cap. boursière
$12.56B
PER (TTM)
122.0x
ROIC (TTM)
-1.23%
Marge brute
98.25%
Autres analyses Peter Lynch
Questions fréquentes
What is CORT's Peter Lynch fit score?
CORT scores 30/100 on our Peter Lynch fit engine. Does not fit Lynch's GARP criteria, growth too low or price too high.
Does Peter Lynch actually own CORT?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends CORT.
How often is this score updated?
CORT's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Outil éducatif, pas un conseil en investissement. Les scores sont calculés à partir de données financières publiques selon les critères publiés de chaque stratégie d'investissement. Nous ne prétendons pas que Peter Lynch possède ou recommande CORT personnellement.
